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Abstract 
Objective: To describe bone mineral density (BMD) and bone mineral content (BMC) in 
children and adolescents infected with the human immunodeficiency virus (HIV), and to 
compare them with data from the National Health and Nutrition Examination Survey IV 
(NHANES IV).
Method: The study included 48 children and adolescents (7 to 17 years old) infected 
with HIV through vertical transmission. BMC and BMD were measured by dual energy 
absorptiometry X-ray, by calculating z-scores based on data from NHANES IV. The 
information on clinical and laboratory parameters of infection by HIV was obtained from 
medical records. Physical activity, calcium intake, and skeletal maturation were also 
assessed. Descriptive and inferential statistical procedures were used, with levels of 
significance set at 5%. 
Results: Seropositive patients presented lower values compared to data from NHANES IV 
in all z-scores of bone mass (mean = −0.52 to −1.22, SD = 0.91 and 0.84, respectively). 
Based on the subtotal z-BMD, there was a prevalence of 16.7% of children and adolescents 
with low bone mass for age. Individuals using protease inhibitors presented a lower total 
z-BMD when compared to the group that did not use (−1.31 vs. −0.79, p = 0.02). There 
were no bone mass differences in relation to physical activity and calcium intake.   
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Introduction
After the advent of antiretroviral therapy (ART), a reduction 
in morbidity and mortality due to human immunodeficiency 
virus (HIV) infection was observed. However, side effects of 
ART have been reported, such as lipodystrophy, metabolic 
disorders, and bone mass alterations.1 In young individuals 
infected with HIV through vertical transmission, prolonged 
drug exposure may potentiate these effects, and significant 
reductions in bone mineral density (BMD) and bone 
mineral content (BMC) have been reported.2-7 Despite 
the controversies, the factors that contribute to these 
decreases are calcium intake deficit, ART that includes 
protease inhibitors (PI), specific antiretrovirals (stavudine-
d4T, tenofovir [TDF], and ritonavir [RTV]), advanced stages 
of infection, and lipodystrophy.3,5,8,9 Although the benefits 
of regular physical activity in maintaining bone health 
is known, few studies have considered this variable in 
relation to BMD/BMC.3,6,7
Peak bone mineral accrual occurs mainly during puberty;10 
thus, concerns about decreases in bone mass in children 
and adolescents living with HIV is increased, as they could 
develop early complications 
This study aimed to describe the BMD and BMC of 
children and adolescents infected with HIV through vertical 
transmission, and to compare these values with those 
of healthy individuals, taking into account age, gender, 
and ethnicity. BMD was also investigated as a function of 
calcium intake, level of physical activity, and the inclusion 
of PI in ART. 
Methods
Ethical aspects
The research followed the ethical guidelines outlined in the 
Declaration of Helsinki and was approved by the Research 
Ethics Committee of the Hospital Infantil Joana de Gusmão 
(HIJG) (No. 077/2009). Parents or legal guardians signed 
the informed consent. 
Subjects
The study sample consisted of 48 children and adolescents 
with HIV infection acquired by vertical transmission, of both 
genders, aged between 7 and 17 years, living in the city of 
Florianópolis, capital of the state of Santa Catarina, Brazil. 
Individuals were selected in a non-probabilistic way from 
the Specialized Care Service of the Hospital Dia - HIJG. 
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humana
Resumo 
Objetivo: Descrever a densidade mineral óssea (DMO) e conteúdo mineral ósseo (CMO) 
de crianças e adolescentes que vivem com o vírus da imunodeficiência humana e compa-
rar com os dados do National Health and Nutrition Examination Survey IV (NHANES IV). 
Método: Participaram do estudo 48 crianças e adolescentes (sete a 17 anos de idade) 
com infecção pelo vírus da imunodeficiência humana adquirida por transmissão vertical. 
A DMO e o CMO foram mensurados pela absorciometria por dupla emissão de raios-X, 
calculando-se escores-z com base nos dados do NHANES IV. Nos prontuários médicos 
foram obtidas as informações dos parâmetros clínicos e laboratoriais da infecção pelo 
vírus da imunodeficiência humana. Foram ainda avaliadas a atividade física, a ingestão 
de cálcio e a maturação esquelética. Utilizaram-se procedimentos da estatística descri-
tiva e inferencial, estabelecendo níveis de significância de 5%. 
Resultados: Os pacientes soropositivos demonstraram valores inferiores comparados aos 
dados do NHANES IV em todos os escores-z da massa óssea (média = −0,52 a −1,22, dp = 
0,91 e 0,84, respectivamente). Com base no z-DMOsubtotal, há uma prevalência de 16,7% 
de crianças e adolescentes com massa óssea reduzida para a idade. Indivíduos que uti-
lizaram inibidores de protease apresentaram um z-DMOtotal inferior, comparado ao grupo 
que não utilizou (−1,31 vs. −0,79; p = 0,02). Não foram encontradas diferenças na massa 
óssea em relação ao nível de atividade física e ingestão de cálcio. 
Conclusões: Na presente amostra, crianças e adolescentes que vivem com o vírus da 
imunodeficiência humana possuem baixa massa óssea para idade, e o uso de inibidores 
de protease parece estar relacionado a tais reduções. 
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda.  
Conclusions: In the present sample children and adolescents living with HIV have low bone 
mass for age, and the use of protease inhibitors appears to be related to such decreases. 
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.  
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The following inclusion criteria were adopted: undergoing 
treatment at HIJG; availability of clinical and laboratory 
information in the medical record; absence of other diseases 
or medications that could alter body composition, considering 
that the main study investigated the alterations of three 
components of body composition.
Study variables, instruments  
and standardizations
Socio-demographic and anthropometric data
During an interview, information was collected on age, 
gender, and ethnicity of children and adolescents infected 
with HIV, as well as on the socioeconomic and educational 
level of parents or guardians. Height and body mass were 
measured by standardized procedures,11 using a Tonelli wall 
stadiometer (120A – Criciúma, Brazil) with an accuracy of 0.1 
cm, and a Tanita digital scale (BF683W – Arlington Heights, 
USA) with an accuracy of 0.1 kg. The measurements were 
performed twice by the same examiner, with technical 
errors of measurement of 0.19 cm and 0.51 kg for height 
and body mass, respectively. Nutritional status was assessed 
by the z-score, based on the parameters of height/age and 
body mass index (BMI)/age.12
Bone mass
Bone mass was measured through dual emission X-ray 
absorptiometry (DXA) on a Hologic device (Discovery WI 
Fan-Bean – Bedford, USA); the attenuation of X-rays was 
computed using a pediatric software. This method is safe, 
as the devices emit radiation from 4.2 to 5.2 μSv, equivalent 
to one day of sunshine. It has high concurrent validity, 
reproducibility, and technical accuracy when measuring 
bone mass.13 In this study, the internal quality control 
included daily calibrations, according to the manufacturer. 
The CV of total BMD during the study period was 1%. During 
the assessments, the subjects used appropriate clothing, 
without shoes, earrings, and/or rings.
Based on the DXA results, the total and subtotal 
BMD and BMC variables were considered (except the 
head). The subtotal is a good measure of accuracy 
and reproducibility, as the total BMD/BMC can dilute 
the alterations in bone mass.14 For logistical reasons, 
the specific parameters of the spinal column, femoral 
head, and 33% radius were not evaluated. Z-scores were 
calculated from the LMS values published by Kelly et 
al.,15 using the supplement LMS Growth for MS Excel, 
developed by Pan & Cole. Brazilian data in the literature 
do not allow the determination of the z-score by age, 
gender, and ethnicity.16 
Human immunodeficiency virus-infection clinical 
data 
Medical records provided clinical (type/time of ART, 
immunological and clinical symptoms classifications) and 
laboratory data (HIV RNA viral load, and TCD4+ and 
TCD8+ lymphocytes) of the HIV infection. Participants 
were classified into the categories of immunosuppression 
and clinical symptoms of HIV evolution according to 
the propositions of the Centers for Disease Control and 
Prevention (CDC).17 HIV RNA viral load was determined by 
the branched DNA method (b-DNA), and TCD4+ and TCD8+ 
lymphocytes were determined by flow cytometry.
Control and lifestyle variables 
Bone age was determined through the radiographic 
evaluation of the left hand and fist, estimated by the 
Greulich-Pyle method,18 performed by an HIJG radiologist 
with extensive experience with the method. 
The level of physical activity was measured objectively by a 
motion sensor (pedometer; [Digi-Walker SW200 – YamaxCorp, 
Tokyo, Japan]), used for five days, two of them during 
the weekend. The use of the pedometer was standardized 
on the right side of the waist above the iliac crest, and 
patients started to use it in the morning, removing it only 
for activities in the water or bath/shower. At the end of the 
day, the subjects and/or guardians wrote down the number 
of recorded steps. This method has a high correlation with 
accelerometry (r = 0.86) and a moderate one with indirect 
measurements of energy expenditure (r = 0.64). 
Individuals were included with data for at least four 
days. Five subjects did not meet this criterion and thus 
a gender-specific median value of steps was used. In the 
absence of physical activity level classification for the 
infected population, the proposed cutoff of 13,000 and 
11,000 steps/day for healthy boys and girls, respectively, 
was used. For teenagers, the cutoff was 10,000 steps/day.19 
These values, on average, correspond to 60 minutes of 
moderate-vigorous physical activity, which classifies youth 
as either active or insufficiently active.19
Calcium intake was assessed using a simplified version of 
the food frequency questionnaire,20 which shows moderate 
validity in estimating calcium (r = 0.70), adjusted for 
intra and interpersonal variability.20 The questionnaire was 
administered to the subjects or guardians (for those younger 
than 13), during an interview with a nutrition student. 
The standardization of portion sizes was established in 
accordance with the suggestion of Pinheiro et al.21 To 
determine the nutritional value of foods, the Brazilian 
Table of Food Composition and the USDA National Nutrient 
Database for Standard Reference were used.22,23
Bone diameter was used to control differences in BMD 
related to body and bone size. It has been suggested that 
DXA is incapable of detecting bone edges in subjects that 
are still growing.24 Thus, femur diameter measurements 
followed standardizations11 and were obtained using a 
digital caliper (Digimess – São Paulo, Brazil) with accuracy 
of 0.01 mm. The technical error of measurement was found 
to be 0.55 mm.
Statistical analysis
A Gaussian distribution was established by the Shapiro-
Wilk’s test, in addition to the analysis of graphic 
representation. Asymmetric data were normalized using 
log10 transformation. Descriptive statistics procedures 
were used in the presentation of data (measurements of 
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central tendency, dispersion, and relative and absolute 
frequencies). In inferential statistics, Student’s t-test, the 
chi-squared test, and analysis of covariance (ANCOVA) were 
performed, adjusting for bone age, body mass, diameter 
of the femur, physical activity, calcium intake, duration of 
ART, and use of PI in ART. The Statistical Package for Social 
Sciences (SPSS) was used for statistical analyses and the 
significance level was set at 5% (a ≤ 0.05 or 95% CI).
Results
Most children and adolescents infected with HIV were under 
the guardianship of the biological family (64.6%), 20.8% lived 
with an adoptive family, and a small number (14.6%) lived 
under the tutelage of the state. The guardians had a degree 
of educational level up to incomplete elementary school 
in 22.9% of the cases, and only 6.3% reported complete 
college/university education. A per capita monthly income 
of up to two Brazilian minimum wages was reported by 
47.9% of the guardians, while 37.5% reported an income 
higher than two Brazilian minimum wages. 
Table 1 shows demographic and lifestyle data. In the 
studied group, there was a similar distribution between 
genders and ethnicity. The mean negative difference 
between bone and chronological age suggests delay in 
skeletal maturation, with no statistical difference between 
the genders. Five teenagers presented delayed skeletal 
maturation, using a cutoff of ≤ −2 standard deviations 
specific for age and gender.18 Negative means of the z-score 
of height for age and of BMI for age were also found, with 
no statistical difference between the genders. 
Regarding lifestyle, inadequate levels of physical activity 
were observed in 68.8% (n = 33), according to the 
pedometry criterion. Regarding calcium intake, 29 (60.4%) 
of the young individuals infected with HIV had inadequate 
calcium levels, when compared to the dietary reference 
intakes (DRIs).25 
In general, the good immunological and virological status 
of individuals infected with HIV is evidenced (Table 2), 
due to the absence of immunosuppression or moderate 
immunosuppression (≈ 75% of the group) and due to 
undetectable HIV RNA viral load (58.3%, n = 28). Over half 
of individuals younger than 13 years of age (58.4%) were 
in the early stages of the disease (N - asymptomatic and 
A - mild symptoms), and 54.2% of adolescents (> 13 years) 
presented the symptoms of acquired immunodeficiency 
syndrome (AIDS). In general, ART was followed by triple 
therapy, and approximately 10% were using some medication 
compatible with viral resistance. 
Regarding bone mass measurements (Table 3), higher 
values were observed in adolescents when compared 
to children (adjusted for gender and BMI, p < 0.001) 
and in males when compared to females (adjusted for 
age and BMI z-score, p < 0.05), reflecting bone mineral 
increase processes and sexual dimorphism, respectively. 
Lower values of total BMD z-score of for age (total 
BMD-z) and subtotal BMD z-score for age (subtotal BMD-
z) were found in females when compared to males (p 
< 0.05), a difference that did not remain significant 
when the subtotal BMD z-score was analyzed for height 
(subtotal BMD-z/ height). The z-scores of BMC and BMD 
showed, in general, negative values for all parameters 
analyzed. 
Considering subtotal BMC-z score, four subjects (males) 
had scores ≤ -2 SD, indicating low bone mineral content 
for age. When analyzing the subtotal BMD z-score, the 
prevalence increased to eight cases (16.7%). These z-scores 
Table 1 Sociodemographic, clinical, and lifestyle parameters of children and adolescents infected with HIV, Florianópolis-SC, 
Brazil, 2011.
Variables Female (n = 24) Male (n = 24) Total (n = 48)
Demographic data    
 Age, mean (SD)a 12.5 (3.1) 12.9 (2.4) 12.7 (2.7)
 Ethnicity, n (%)   
 White 14 (58.3) 13 (54.2) 27 (53.3)
 Black/Mixed-race 10 (41.7) 11 (45.8) 21 (43.8)
 Bone age, mean (SD)a 12.4 (2.9) 12.3 (3.7) 12.4 (3.3)
 Difference BA-CA, mean (SD)a −0.12 (1.20) −0.42 (1.11) −0.27 (1.1)
Anthropometric and life style data  
 Weight, mean (SD)a 39.2 (10.7) 41.3 (14.3) 40.3 (12.5)
 Height, mean (SD)a 144.5 (13.7) 150.9 (16.3) 147.7 (15.2)
 z-BMI/A, mean (SD)b −0.03 (0.77) −0.50 (0.95) −0.27 (0.88)
 z-H/A, mean (SD)b −0.71 (0.84) −0.55 (1.02) −0.63 (0.93)
 PA (steps/day), mean (SD)a,c 9179 (4539) 11797 (5922) 10488 (5385)
 Calcium (mg/day), mean (SD)a 1010.4 (406.3) 1102.1 (353.6) 1057.3 (378.1)
BA-CA, bone age minus chronological age; PA, physical activity; SD, standard deviation; z-BMI/A, body mass index z-score for age; 
z-H/A, height z-score for age. 
aStudent’s t-est for independent samples.
bAnalysis of covariance adjusted by bone age (mean of 12.4 years).
cStandardized by log-transformation (log10). No significant differences were found between genders in the analyzed variables  
(p > 0.05).
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were calculated based on specific values for age, gender, 
and ethnicity.15 
There was no difference in the proportions of subjects 
with subtotal BMD z-score ≤ -2 SD between genders or ages. 
Although the z-scores between ≤ −2 and ≤ −1 SD did not 
define low bone mass for age, 27 children and adolescents 
(56.2%) had low values of subtotal BMC-z-score, whereas 
lower values of subtotal BMD-z-score were observed in 21 
subjects (43.7%). 
Lower total z-BMD was observed in the group that used 
PI in ART, regardless of body mass, femur diameter, bone 
age, physical activity, calcium intake, or ART duration 
(Table 4).
There were no significant differences in total z-BMD 
score of children and adolescents infected with HIV, 
compared by level of physical activity or daily calcium 
intake (p > 0.05). There were no significant differences in 
total z-BMD between stages N and A versus B and C, stages 
1 and 2 versus 3, undetectable viral load versus viral load > 
50 copies/mL, and absence/moderate immunosuppression 
versus severe immunosuppression (p > 0.05). All these 
analyses were adjusted for body mass, femur diameter, 
bone age, physical activity, daily calcium intake, time of 
ART, and use of PI in ART. 
Discussion
The main finding of this study was the low z-score of 
bone mass in children and adolescents infected with HIV, 
when compared to healthy subjects from NHANES IV. The 
prevalence of low subtotal BMD for age was estimated at 
43.7%, considering z-scores < −1 SD. 
These data are innovative in the national literature, 
and reproduce research findings from other countries 
using absolute values,2,4 z-score,3,5,7 or quantitative 
Table 2 Clinical, immunological and virological parameters in children and adolescents infected with human 
immunodeficiency virus, Florianópolis-SC, Brazil, 2011.
Variables Female (n = 24) Male (n = 24) Total (n = 48)
Infection parametersa
TCD4+ lymphocytes (cells/µL) 787 (544-961) 731 (528-1,137) 747 (531-1,088)
TCD4+ lymphocytes (%) 31.8 (22.1-37.3) 30.5 (26.4-35.3) 31.5 (23.3-35.6)
TCD8+ lymphocytes (cells/µL) 1,093 (810-1,249) 1,082 (715-1,463) 1,089 (746-1,430)
HIV RNA viral load (copies/mL) 49 (49-1,640) 49 (49-491) 49 (49-1,023)
HIV RNA viral load (log10) 1.69 (1.69-2.69) 1.69 (1.69-2.69) 1.69 (1.69-3.00)
CDC symptomsb   
 < 13 years, n (%)   
 A 8 (61.5) 2 (18.2) 10 (41.7)
 B − 5 (45.4) 5 (20.8)
 C 3 (23.1) 2 (18.2) 5 (20.8)
 > 13 years, n (%)  
 1 2 (18.2) 1 (7.7) 3 (12.5)
 2 2 (18.2) 6 (46.2) 8 (33.3)
 3 7 (63.6) 6 (46.2) 13 (54.2)
CDC immunosuppression,b n (%)  
 1 3 (12.5) 6 (25.0) 9 (18.8)
 2 15 (62.5) 13 (54.2) 28 (58.3)
 3 6 (25.0) 5 (20.8) 11 (22.9)
HIV RNA viral load, n (%)   
 Undetectable 13 (54.2) 15 (62.5) 28 (58.3)
 50-10,000 copies/mL 10 (41.7) 8 (33.3) 18 (37.5)
 > 10,000 copies/mL 1 (4.2) 1 (4.2) 2 (4.2)
Antiretroviral therapy,c n (%)
 2 NRTI + 1 NNRTI 10 (41.7) 8 (33.3) 18 (37.5)
 2 NRTI + 1 PI 11 (45.8) 11 (45.8) 22 (45.8)
 Another regimend 2 (8.3) 4 (16.7) 6 (12.5)
CDC, Centers for Disease Control and Prevention; HVI, human immunodeficiency virus; NNRTI, non-nucleoside reverse-
transcriptase inhibitors; NRTI, nucleoside reverse-transcriptase inhibitors; PI, protease inhibitors.
aMedian and interquartile values.
bCDC (2008). 
cTwo individuals do not receive antiretroviral therapy.
dn = 6, of which: 2 NRTI (n = 2), 1 NNRTI + 1 PI (n = 1), 1 NRTI + 1 NNRTI + 1 PI (n = 1), 2 NRTI + 1 NNRTI + 1 PI (n = 1) and 1 NRTI 
+ 2 PI + 1 integrase inhibitor (n = 1).
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ultrasound measurements.6 However, the results found 
are in disagreement with two studies. The first found low 
bone mass only through computed tomography assessment, 
inferring the inability of DXA to assess bone mass in subjects 
with small bones.24 For this reason, femur diameter was 
used in the present study to adjust the values for bone 
size. The second study found no decreases in bone mass in 
a small number of antiretroviral treatment-naïve children 
who were infected through horizontal transmission,26 
probably due to the fact that their health status, growth, 
and maturation were little affected by the short time of 
exposure to HIV, in addition to the absence of antiretroviral 
therapy, which would promote greater bone integrity. 
HIV infection and the host’s response are involved 
in alterations in bone mass. In animal models, bone 
remodeling was induced by high activity of C-terminal 
collagen telopeptide and an increase in the number of 
osteoclasts, given the high activity of the receptor activator 
of NF-kB ligand.27 In vitro analyses have demonstrated that 
HIV-specific proteins interfere in the differentiation of 
mesenchymal stem cells into osteoblasts; they also reduce 
the secretion of regulatory molecules and transcription 
factors activity of osteoblasts.28 Additionally, HIV infection 
reduces the production of IGF-1.6,7 HIV increases the 
production of interleukin-6 and stimulates the formation 
and activity of osteoclasts through the autocrine/paracrine 
factor, reducing bone mass.6,7 
Nearly half of the children and adolescents in the sample 
had bone mass < -1 SD when compared to data from NHANES 
IV. However, this prevalence should be viewed with some 
caution. Kocks et al.29 demonstrated that several databases 
used to build the z-scores can be highly correlated, but the 
values may differ significantly, varying in the proportion 
of subjects with low bone mass for age (15.4% to 27.9%).29 
Regarding the data from NHANES IV,15 as they derive from 
a representative sample of healthy young individuals and 
are shown by age, gender, and ethnicity, they allowed for 
the calculation of specific z-scores. This strategy enabled 
a further discriminated analysis of bone health in children 
and adolescents infected with HIV. 
In the present study, the mean total BMD z-score was 
significantly lower in the group that used PI in ART, when 
compared to those without PI, regardless of body mass, 
femur diameter, bone age, level of physical activity, 
calcium intake, and time of ART (Table 4). The deleterious 
effect of PI on bone mass has been demonstrated by 
the alteration of gene expression, which induces local 
inflammatory activity and the consequent reduction in the 
activity of osteoblasts exposed to ritonavir.30 Exposure to 
lopinavir (LPV/r) produces a decrease in gene expression 
and activity of the alkaline phosphatase enzyme of 
osteoblasts, as well as a decrease in calcium deposits and 
an increase in osteoclast activity.31 
In this study, 25 of the 26 subjects in the group that 
included PI in ART received low-dose ritonavir in addition 
to LPV/r. This specific PI did not demonstrate significant 
reductions in BMC in one study;9 however, the results of the 
same study9 showed reductions in BMC of the lumbar spine 
of those who received full-dose ritonavir. Furthermore, 
patients who received PI in this sample also received 
d4T and TDF (3/26 and 5/26, respectively), indicated as 
modulators in bone mass decrease.8,9 These antiretrovirals 
were present only in ART with PI, so it can be assumed 
that the reductions found in the group that uses PI with 
ART may have been influenced by the three associated 
antiretrovirals (LPV/r, d4T, and TDF ). 
There were no significant differences in bone mass of the 
subjects regarding the physical activity recommendations, 
when controlled for other covariates. The positive 
association between physical activity and bone mass in 
healthy subjects is demonstrated by performing high-
intensity activities, or with high gravitational or muscular 
load, promoting osteogenic stimulus.32 In this context, 
some possible limitations that may explain the findings are 
that the specific sites in bone mass were not assessed, the 
measured physical activity represented only the period of 
data collection, the pedometry cut-off is nonspecific in the 
HIV group, and the size of the analyzed group may have 
reduced the power of the statistical analyses. 
Meeting the recommendations for daily calcium intake 
showed no significant influence on bone mass. O’Brien 
et al.5 found reductions in bone mass in a group of girls 
infected with HIV, which were attributed to inadequate 
calcium intake (20% to 50% below the recommendations) 
and to a multifactorial process. Calcium intake is usually 
determined through the use of the 24-hour food recall. 
Table 4 Analysis of covariance of the total BMD z-score in HIV-infected children and adolescents using protease inhibitor 
antiretrovirals in the treatment, Florianópolis, Florianópolis-SC, Brazil, 2011.
Total BMD Z-score  Infected by HIV    
 HAART without PI (n = 19)  HAART with PI (n = 26)  F* p
Crude mean (SE) −0.84 (0.19) −1.26 (0.17) 2.717 0.106
Confidence interval −1.23; −0.44 −1.61; −0.92  
Adjusted mean (SE) −0.79 (0.16) −1.31 (0.15) 5.433 0.025
Confidence interval −1.11; −0.46 −1.60; −1.01    
BMD, bone mineral density; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; PI, protease inhibitor; 
SE, standard error.
*Analysis of covariance adjusted by body mass, femur diameter (mean = 85.4 mm), bone age, physical activity, calcium ingestion, 
and time of HAART (mean = 8.5 years). Total BMD z-score: z-score of total bone mineral density for age.
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In the present study, this variable was estimated using 
a semiquantitative food frequency questionnaire, which 
despite the moderate validity (r = 0.70),20 may have 
underestimated values.
There were no differences in bone mass due to the 
evolution of clinical symptoms of HIV infection, confirming 
some findings in the literature.4,5 However, other studies3,6 
found that individuals in advanced stages present reductions 
in BMD and impaired bone quality and metabolism. In the 
present study, it was necessary to divide the group into 
different age groups (children [< 13 years] and adolescents 
[> 13 years])17 to meet the infection classification system 
adopted by the CDC. There was no difference in bone 
mass in relation to immunosuppression, confirming the 
findings of Mora et al.4 The status of HIV RNA viral load 
(undetectable versus > 50 copies/mL) also did not affect 
BMD. Rapid immunological and virological alterations can 
occur due to success or failure of the pharmacological 
interventions, whereas alterations in bone mass are slower 
and require approximately six months to be detected;14 this 
may partly explain the findings. 
The present study has other limitations that should be 
considered when interpreting the data: the cross-sectional 
design does not allow causality inference; the evaluated 
subjects represented, on average, individuals with good clinical 
and demographic characteristics, which restricts, in part, the 
external validity of the findings. However, the decrease in 
bone mass remains clear and the findings are quite distressing, 
as lower values tend to remain reduced with increasing age 
and, moreover, the highest bone mineral increase occurs 
in childhood and adolescence10 and interruptions to this 
process may determine increased risk of osteopenia and early 
osteoporosis. Prolonged use of ART may occur in HIV infection, 
potentiating the reduction in bone mass.
This study reinforces the low bone mass for age in children 
and adolescents infected with HIV, regardless of the bone 
parameter used, when compared to data from NHANES 
IV. The use of PI in ART is related to reductions in bone 
mass, regardless of confounding factors. No differences 
were observed in bone mass in relation to physical activity 
and daily calcium intake; however, a small percentage of 
subjects who met both recommendations was observed in 
the group. Interdisciplinary interventions are necessary to 
promote physical activity and adequate nutrient intake in 
order to minimize the impact of HIV infection and ART, thus 
contributing to bone health. 
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